Role of Medium Chain Triglycerides (Axona®) in the Treatment of Mild to Moderate Alzheimer’s Disease

Medium Chain Triglyceride Oil Consumption as Part of a Weight Loss Diet Does Not Lead to an Adverse Metabolic Profile When Compared to Olive Oil

(2013) Marie-Pierre St-Onge et al.   JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION

Positive argument for debate in J Neural Transmission: Alzheimer’s disease: are we intervening too late? Yes, by years if not decades

(2012) Thomas B. Shea et al.   JOURNAL OF NEURAL TRANSMISSION

Education and Dementia in the Context of the Cognitive Reserve Hypothesis: A Systematic Review with Meta-Analyses and Qualitative Analyses

(2012) Xiangfei Meng et al.   PLoS One

Cognitive activity, education and socioeconomic status as preventive factors for mild cognitive impairment and Alzheimer's disease

(2012) Christine Sattler et al.   PSYCHIATRY RESEARCH

Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study

(2011) Samuel T Henderson et al.   BMC Medical Genetics

Medical Foods for Alzheimerʼs Disease

(2011) Raj C. Shah   DRUGS & AGING

Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial

(2009) Samuel T Henderson et al.   Nutrition & Metabolism

SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer's Disease: Aβ-Degrading Enzymes in Alzheimer's Disease

(2008) James Scott Miners et al.   BRAIN PATHOLOGY

The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective

(2008) Solomon S Shaftel et al.   Journal of Neuroinflammation

Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses

(2008) Lars Bertram et al.   NATURE REVIEWS NEUROSCIENCE

Ketone bodies as a therapeutic for Alzheimer’s disease

(2008) Samuel T. Henderson   Neurotherapeutics